Personalized medicine in metastatic colorectal cancer treated with anti-epidermal growth factor receptor agents: A future opportunity?

摘要: Treatment options for colorectal cancer have increased substantially in the past decade, with introduction of novel biological therapies targeting cancer-specific molecules leading to significantly improved outcomes. Despite access these treatments, we are not yet an era where can fully personalize treatment choices patients cancer. A number prognostic and predictive markers been identified that appear be directly related sensitivity targeted therapies, such as those against epidermal growth factor receptor. However, sensitivities individual tumors toward different agents more complex. It seems a complete molecular signature tumor must taken into account when making choices. In absence having elucidated influence or markers, other surrogate early success may useful determining whether continue particular agent. this review, discuss role choosing appropriate patient, along use measuring depth response agent assist decisions on therapy